Related Experiment Video
Updated: Nov 10, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer
Sebastian Griesing1, Bin-Chi Liao2, James Chih-Hsin Yang3,2,4
1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
Background/Aim:
Successful therapy of EGFR-mutant NSCLC remains a challenging task despite initial benefits with the usage of EGFR tyrosine kinase inhibitors. Cancer immunotherapy has shown promising results in certain tumors, but response rate in EGFR-mutant NCLC is low, because these tumors are thought to have weak immunogenicity.
Materials And Methods:
We used data from in vivo NSCLC databases as well as from in vitro cell culture experiments to investigate the regulation of CD73 by EGFR.
Results:
EGFR expression was correlated with CD73 expression in patients' datasets, with EGFR-mutant tumors showing higher expression than their EGFR wildtype counterparts. Treatment of EGFR-mutant NSCLC cell lines with EGFR TKI reduced expression of CD73 at both mRNA and protein level. Among EGFR downstream signaling pathways, the Ras-Raf-ERK pathway was involved in the regulation of CD73 expression directly via ERK1/2 without the engagement of RSKs or MSKs.
Conclusion:
The results of this study may provide novel therapeutic strategies for the treatment of oncogene-driven NSCLC.
Insights
EGFR tyrosine kinase inhibitors (TKIs) can decrease CD73 expression in EGFR-mutant non-small cell lung cancer (NSCLC) by regulating the Ras-Raf-ERK pathway. This finding may lead to new treatments for oncogene-driven NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) offer initial benefits for EGFR-mutant non-small cell lung cancer (NSCLC) but challenges remain.
- Cancer immunotherapy shows limited efficacy in EGFR-mutant NSCLC due to presumed weak tumor immunogenicity.
Purpose of the Study:
- To investigate the relationship between EGFR and CD73 expression in NSCLC.
- To explore the mechanism by which EGFR signaling regulates CD73.
Main Methods:
- Analysis of in vivo NSCLC patient datasets.
- In vitro cell culture experiments with EGFR-mutant NSCLC cell lines.
- Investigation of EGFR downstream signaling pathways, including Ras-Raf-ERK.
Main Results:
- EGFR expression positively correlated with CD73 expression in NSCLC patient data.
- EGFR-mutant tumors exhibited higher CD73 expression compared to EGFR wildtype tumors.
- EGFR TKI treatment reduced CD73 expression at both mRNA and protein levels in EGFR-mutant NSCLC cell lines.
- The Ras-Raf-ERK pathway, specifically ERK1/2, was identified as a key regulator of CD73 expression, independent of RSKs or MSKs.
Conclusions:
- EGFR signaling directly influences CD73 expression in NSCLC.
- Targeting EGFR may modulate CD73, potentially enhancing anti-tumor immunity.
- These findings suggest novel therapeutic strategies for EGFR-driven NSCLC.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
01:24Regulation of Angiogenesis and Blood Supply
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway